Literature DB >> 29052234

Measuring precision in bioassays: Rethinking assay validation.

Michael P Fay1, Michael C Sachs2, Kazutoyo Miura3.   

Abstract

The m:n:θb procedure is often used for validating an assay for precision, where m levels of an analyte are measured with n replicates at each level, and if all m estimates of coefficient of variation (CV) are less than θb , then the assay is declared validated for precision. The statistical properties of the procedure are unknown so there is no clear statistical statement of precision upon passing. Further, it is unclear how to modify the procedure for relative potency assays in which the constant standard deviation (SD) model fits much better than the traditional constant CV model. We use simple normal error models to show that under constant CV across the m levels, the probability of passing when the CV is θb is about 10% to 20% for some recommended implementations; however, for extreme heterogeniety of CV when the largest CV is θb , the passing probability can be greater than 50%. We derive 100q% upper confidence limits on the CV under constant CV models and derive analogous limits for the SD under a constant SD model. Additionally, for a post-validation assay output of y, we derive 68.27% confidence intervals on either the mean or log geometric mean of the assay output using either y±s (for the constant SD model) or log(y)±rG (for the constant CV model), where s and rG are constants that do not depend on y. We demonstrate the methods on a growth inhibition assay used to measure biologic activity of antibodies against the malaria parasite. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  assay qualification; coefficient of variation; functional assay; relative potency assay; standard deviation interval

Mesh:

Year:  2017        PMID: 29052234      PMCID: PMC5771887          DOI: 10.1002/sim.7528

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Fit-for-purpose method development and validation for successful biomarker measurement.

Authors:  Jean W Lee; Viswanath Devanarayan; Yu Chen Barrett; Russell Weiner; John Allinson; Scott Fountain; Stephen Keller; Ira Weinryb; Marie Green; Larry Duan; James A Rogers; Robert Millham; Peter J O'Brien; Jeff Sailstad; Masood Khan; Chad Ray; John A Wagner
Journal:  Pharm Res       Date:  2006-01-12       Impact factor: 4.200

2.  Statistical inference for the within-device precision of quantitative measurements in assay validation.

Authors:  Jen-Pei Liu; Li-Tien Lu; C T Liao
Journal:  J Biopharm Stat       Date:  2009-09       Impact factor: 1.051

3.  An assessment of the 4-6-20 rule for acceptance of analytical runs in bioavailability, bioequivalence, and pharmacokinetic studies.

Authors:  R O Kringle
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

4.  Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Authors:  Elissa M Malkin; David J Diemert; Julie H McArthur; John R Perreault; Aaron P Miles; Birgitte K Giersing; Gregory E Mullen; Andrew Orcutt; Olga Muratova; May Awkal; Hong Zhou; Jin Wang; Anthony Stowers; Carole A Long; Siddhartha Mahanty; Louis H Miller; Allan Saul; Anna P Durbin
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 5.  Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

Authors:  J Cummings; F Raynaud; L Jones; R Sugar; C Dive
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

6.  Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays.

Authors:  Kazutoyo Miura; Bingbing Deng; Gregory Tullo; Ababacar Diouf; Samuel E Moretz; Emily Locke; Merribeth Morin; Michael P Fay; Carole A Long
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

  6 in total
  1 in total

1.  Assessing the functional impact of PfRh5 genetic diversity on ex vivo erythrocyte invasion inhibition.

Authors:  Alassane Mbengue; Amy K Bei; Adam J Moore; Khadidiatou Mangou; Fatoumata Diallo; Seynabou D Sene; Mariama N Pouye; Bacary D Sadio; Ousmane Faye
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.